3Kahn HJ, Fekete E, From L. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor Xllla. Hum PathoL 2001, 32( 1 ): 50-56.
4Maire G, P6deutour F, Coindre JM. COL1AI-PDGFB gene fusion demonstrates a common histogenetic origin for dermatofibrosarcoma protuberans and its granular cell variant. Am J Surg Pathol,2002, 26(7): 932-937.
5Kumar R, Rodriguez V, Khan SP, et al. Postradiation dermatofi- brosarcoma protuberans in a patient with Wilms tumor. J Pediatr Hematol Oncol, 2011, 33(8): 635-636.
6Kamiya T, Saga K, Kaneko R, et al. Postradiation dermatofi- brosarcoma protuberans. Acta Derm Vene reol, 2006, 86 (2): 152-153.
7Parlette LE, Smith CK, Germain LM, et al. Accelerated growth of dermatofibrosarcoma protuberans during pregnancy. J Am Acad Dermatol, 1999, 41(5 Pt 1 ): 778-783.
8Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protu- berans: treatment results of 35 cases. Radiother Oncol, 2000, 57(2): 175-181.
9Rutkowski P, Debiec-Rychter M, Nowecki Z, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesy- late with or without surgical resection. J Eur Acad Dermatol Venereol, 2011, 25 (3): 264-270.
